Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (10036)	10/31/2008 9:35:52 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 10345

deleted

To: fred hayes who wrote (10036)	11/2/2008 12:49:39 PM
From: idos	4 Recommendations Read Replies (2) \| Respond to of 10345

The TOUCH and TYGRIS programs along with docs&patients high awareness of signs&symptoms of PML, lead to early diagnosis and treatment and to better prognosis. On the other hand, Tysabri's MoA and the fact that JC virus can remain in a latent stage in different sites such as the kidneys, and may undergo reactivation, make me think (I do hope I'm wrong) that rates of PML will rise. As long as there is no longterm safety data for Tysabri and no reliable method for screening of potential patients at PML risk, I don't think that the bar to treating a patient will be lowered.